Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Regarding Sorrento Therapeutics' COVID-19 antibody test COVI-TRACK, Selvaraju reported that it is currently being evaluated for emergency use authorization, which it is expected to be granted in the coming weeks. Subsequently, the biopharma will make it available for distribution to clinical testing sites around the world, leveraging its existing relationships, such as with Cardinal Health, in doing so. At the start, Sorrento expects to manufacture up to 5 million test kits per month.
Selvaraju presented five reasons why COVI-TRACK is a competitive testing solution. It produces results quickly, in about eight minutes, and detects immunoglobulin G and immunoglobulin M antibodies. The test's specificity, the ability to not generate false positives, and its sensitivity, the ability to not generate false negatives, exceed the 95% and 90% standards, respectively, when many of the existing tests "are woefully inaccurate," the analyst noted. Lastly, Sorrento has savvy and experience with antibodies, Selvaraju wrote.
The need for COVI-TRACK "is likely to be healthy" and "persist for the foreseeable future," indicated Selvaraju. As such, in the U.S. alone, the vaccine could generate $50 million-plus a year for Sorrento Therapeutics.
Selvaraju pointed out that in other recent news, the company completely prepaid both of its outstanding term loans, one for $100 million and another for $20 million. Now debt free, the biopharma should be better positioned going forward for "operational flexibility and potential strategic combinations."
Word is that Sorrento is partnering with Cardinal Health to market COVI-TRACK(approval days away).
"Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States. Its headquarters are based in Dublin, Ohio and Dublin, Ireland. The company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical products, including gloves, surgical apparel, and fluid management products. In addition, it operates the largest network of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States." It has over 50,000 employees worldwide and annual earnings exceeding $7 billion.
Another D44 summary of the Sorrento programs ....
"Look for one PR followed by another elevating Sorrento shares to new successive highs in the next several months.
Not only are investors awaiting EUA approval of it's COVIDTRACK test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus. Investors are also waiting on positive news for approval of their antibody cocktail "COVI-SHIELD" STI-1499..the company's preventative treatment.
NIH Clinical trial listing posted 6/25 & 7/1 waiting for FDA approvals to initiate..
NEW
Not yet recruiting
Study to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19
Condition
Covid-19
Interventions:
Biological: STI-1499
Other: Standard of Care
Drug: Placebo
Locations:
NEW
Not yet recruiting
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19
Condition
Covid-19
Interventions:
Drug: Abivertinib
Other: Standard of Care
Locations:
Longer term..
The future of Sorrento lies in it's core Oncology & Pain programmes. Core programs listed in order of importance to the company. COVID is the most recent addition to the company's platforms. As you can see below from Sorrento's extensive research.. cancer & pain
are core to the company's
programmes..
Immuno-Oncology
Key Programs
*CART (MultipleMyeloma)
Ph I
*CD38 DAR-T (Multiple Myeloma)
Preclinical
*CD38 ADC (Amyloidosis)
Ph I
*Seprehvir™ (Solid Tumors)
Ph I
Pain Key Programs
*RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain)
Ph II
*RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA)
Ph II
*RTX (resiniferatoxin) Intra-articular route
(TKR Deferment)
Preclinical
Lymphatic DeliveryKey Programs
*Sofusa® anti-TNF (Autoimmune)
Preclinical
*Sofusa® anti-PD-1
(ImmunoOncolog)
Preclinical
COVID-19 Programs
Key Programs
*COVIDGUARD
Preclinical
*COVIDSHIELD
Preclinical
*COVIDTRAP
Preclinical
Sorrento's many Partnerships & Subsidiaries
SCILEX
58% ownership stake.
IPO pending 2020
BIOSERV
100% owned subsidiary.
CONCORTIS/ LEVENA 100% owned subsidiary
ARK ANIMAL HEALTH
100% owned subsidiary
YUHAN
35% ownership of ImmuneOncia JV
LEE PHARM
Sorrento licensee. Collaboration
CELULARITY
25% ownership stake
JDA ( joint development agreement) $5 ml
MABPHARM
Collaboration & development
https://sorrentotherapeutics.com/partnership/
No other Covid stock is advancing 11 Covid technologies .
No other Covid stock has 34% insider ownership .
No other Covid stock has blockbuster potential cancer and non-opioid pain programs.
Join the short squeeze ....or just watch. Enjoy.
Another great summary of some Sorrento non-covid programs by D44....
"Sorrento's platforms & pipeline are far more expansive than most microcap bioscience companies. Core to Sorrento's research is immunoncology therapeutics for Cancer & Cancer pain.. CAR-T CD-38 is in the process of being transformed to DAR-T which uses healthy donor cells.. off the shelf vs. patients own T-cells shortening critical time to the patient while reducing costs. Cancer pain therapy RTX (resintoxferin) is in phase ll with readout due in March 2021. RTX Intra-articular route Knee OA also phase ll is due for a readout 2H 2020.. Plll scheduled to start August 2020. Company also a owns 58% stake in Scilex whose SP-102 will be the first FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US alone. Scilex is set to IPO sometime in the 2H 2020 delayed due to SARS-COV2.
Sorrento is also partnered with Celularity whose CYNK-001 NK natural killer cell for multiple myeloma is in Pll. CYNK-001 for Coronavirus has recently begun recruiting.
Sorrento licenses fully human anti-PD-L1 mAb STI-A1014 to Lee Pharm for the Chinese market. SOFUSA anti-PD1 for Cutaneous T-Cell Lymphoma & SOFUSA TNK for the treatment of Rheumatoid Arthriti are being developed for the US market.
Last but most importantly Sorrento has one of the industries largest fully human antibody libraries in the biopharmaceutical industry. Sorrento's G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences. Sorrento has successfully identified fully human antibodies against over 100 clinically-relevant high-impact oncogenic targets, including PD-1, PD-L1, CD38, CD123, CD47, VEGFR2, and CCR2.
You should spend some time reviewing their presentations on Sorrentotherapeutics.com.
Moderna or Inovio platforms / pipeline cannot compare in breadth nor are they as advanced in their research as Sorrento. Moderna & Inovio have had their initial run from COVID-19. What I can tell you..Sorrento represents a much larger opportunity long term than those two & is currently in it's infancy for valuation."
Sorrento often releases news on a Friday. They do have 24 potential news releases that could come at any time. Without news it could dip with profit taking in the morning and recover later in the day as investors look forward to next week.
WITH news it could move into the double digits.
Remember THE PHONEY LAWSUITS ARE NOW A THING OF THE PAST. Shorters have lost their only argument!
This thoughtful scientific article don't mention Sorrento but it explains why it is so important that Sorrento is testing a variety of vaccines and therapies . No other company has as many shots on goal as Sorrento. Corona viruses are a tough target!
https://www.cnn.com/2020/07/08/opinions/covid-19-treatment-reason-for-hope-haseltine/index.html
Shorters hate this list. They are now shortening it on Yahoo!. Omitting the last 10 items....wonder why? Sorrento has industry leading 11 Covid programs. Here is pending news update (as of July 8)
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
Sorrento will have at least one Covid phase 1 and another Covid phase 2 in a few weeks. I look forward to these and several more in the near future. Sorrento's scientists are very capable. Meanwhile there could be some non-opioid pain or cancer trial news at any time. That is the beauty of have 3 wide and deep program areas.
‘This is getting out of control,’ says infectious disease expert about coronavirus
Kristin Myers Yahoo Finance July 6, 2020
As coronavirus cases spike across the country, one infectious disease expert says the wave of outbreaks is “getting out of control,” as economies and businesses reopen and some states see social distancing standards relax.
“There is an old adage in infectious disease that a virus isn’t going anywhere until it’s eliminated everywhere,” Dr. Michael Saag, director of the Infectious Disease Division at the University of Alabama at Birmingham School of Medicine, told Yahoo Finance.
“Why don’t we direct our attention on all of us working together to have everybody wear a mask, stay at home at least for the time being,” he said. “Sorry, I know it’s not fun. But this is getting out of control.”
The United States is rapidly approaching 3 million positive coronavirus cases according to the Johns Hopkins University COVID-19 tracker, as the average case count in the country hits another record high.
“I’m afraid that the status quo is not going to cut it from this point forward,” said Saag. “At least for the next eight weeks. So we’re going to probably have to do something different.”
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), warned last week that daily case counts could skyrocket to 100,000 coronavirus cases a day if measures weren’t taken to curb the virus.
“All of the southern states — and some others — basically became Missouri. They’re the ‘show-me’ state. They didn’t believe this was real,” Saag said. “Guess what. It’s very real. So we’ve got to buckle down and take care of ourselves, or else we might see another doubling of the cases up to 100,000 as Dr. Fauci said.”
Saag said that even amid spiking case counts, there is a “window of opportunity” to get coronavirus under control. The infectious disease expert said we should all behave as if we were “80 years old with underlying health conditions.” If we did, he explained, we would all “stay at home, avoid large crowds, and wear a mask everywhere we go.”
“All of us want to avoid another shelter at home environment,” he said, “but if we don’t get this right, we’re headed that way.”
Most concerning to Saag is the “overwhelming” of health care systems. “Hospitals are starting to fill up here in the South,” he said.
“All of us are worried about that,” he said. “And that’s a nightmare scenario — there is not going to be any room at the end. And patients won’t be able to get in with or without COVID.”
Each year I get the flu vaccine even though it is only 40-60% effective. Years ago I got the Zostavax shingles vaccine even though I knew it was only 50% effective. More recently I got the Shingrex shingles vaccine because it is 90% effective.
Dr.Fauci said he'd be satisfied with a Covid vaccine even if it was only 70-75% effective.
Sorrento has the T-VIVA-19 vaccine which has been 80% effective in animals. And they have several more vaccines which may be more effective. And of couse they have 1499 antibody which may be 100% effective as a therapeutic.
Sorrento is aiming for BEST-IN-CLASS Vaccines and therapeutics! I like their chances!
Sorrento has 11 anti-covid technologies and very valuable non-opioid pain and cancer drugs. However some say because of its Covid portfolio alone it will end up with a larger market cap than Moderna. A greater market cap than MODERNA? It has over 370 million shares and reached about $90. That gave it a $33 billion market cap. Sorrento has about 209 million shares and to reach a $33 billion market cap the share price would need to be about $160. Please check my math...but $160 would be nice.
But that offer obviously was not based on DMD approval or Covid trial success. If I were CAPR management I would wait to have those two successes in hand before I partnered.
I am confused by the notion that we will get all this news this week. Management hasn't even announced the DMD meeting with the FDA. The Covid trial has just started. Exosome animal trials take time. Why would CAPR's excellent management do a deal before they have the good news from these events? It doesn't make sense to me. But I could be wrong.
Another useful post by D44 on Yahoo!
"Sorrento..much more than another COVID-19 play. If your invested.. you have alot to cheer about. Not only are investors awaiting EUA approval of it's COVIDTRACK test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus. Investors are also waiting on positive news for approval of their antibody cocktail "COVI-SHIELD" STI-1499..the company's preventative treatment.
NIH Clinical trial listing posted 6/25 & 7/1 waiting for FDA approvals to initiate..
NEW
Not yet recruiting
Study to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19
Condition
Covid-19
Interventions:
Biological: STI-1499
Other: Standard of Care
Drug: Placebo
Locations:
NEW
Not yet recruiting
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19
Condition
Covid-19
Interventions:
Drug: Abivertinib
Other: Standard of Care
Locations:
Longer term..
The future of Sorrento lies in it's core Oncology & Pain programmes. Core programs listed in order of importance to the company. COVID is the most recent addition to the company's platforms. As you can see below from Sorrento's extensive research.. cancer & pain
are core to the company's
programmes..
Immuno-Oncology
Key Programs
*CART (MultipleMyeloma)
Ph I
*CD38 DAR-T (Multiple Myeloma)
Preclinical
*CD38 ADC (Amyloidosis)
Ph I
*Seprehvir™ (Solid Tumors)
Ph I
Pain Key Programs
*RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain)
Ph II
*RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA)
Ph II
*RTX (resiniferatoxin) Intra-articular route
(TKR Deferment)
Preclinical
Lymphatic DeliveryKey Programs
*Sofusa® anti-TNF (Autoimmune)
Preclinical
*Sofusa® anti-PD-1
(ImmunoOncolog)
Preclinical
COVID-19 Programs
Key Programs
*COVIDGUARD
Preclinical
*COVIDSHIELD
Preclinical
*COVIDTRAP
Preclinical
Sorrento's many Partnerships & Subsidiaries
SCILEX
58% ownership stake.
IPO pending 2020
BIOSERV
100% owned subsidiary.
CONCORTIS/ LEVENA 100% owned subsidiary
ARK ANIMAL HEALTH
100% owned subsidiary
YUHAN
35% ownership of ImmuneOncia JV
LEE PHARM
Sorrento licensee. Collaboration
CELULARITY
25% ownership stake
JDA ( joint development agreement) $5 ml
MABPHARM
Collaboration & development
https://sorrentotherapeutics.com/partnership/
In July and August we can expect most of these 24 news items will be released. If they release 3 a week they would run to August 31. I expect 2 or 3 this week.
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid ARDS begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by this portfolio.
I apologize for saying $8 billion. Dr. Ji said "over $10 billion".
I had not heard Dr. Ji speak about the $8 Billion market blockbuster drug before...
Shorters hate this list. They are now shortening it on Yahoo!. Omitting the last 10 items....wonder why? Sorrento has industry leading 11 Covid programs. Here is pending news update (as of July 1)
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
And what happens to the buyout price if there's a bidding war?
"It can take several months from the time one company makes a buyout offer for another until the deal closes. Typically, the share owners of the target company must vote on whether to accept the offer. When the buyout offer is made, the share price of the company being bought usually jumps up to a price close to the buyout value and will stay there until the deal closes. An extra bonus for investors can occur if another company comes in with a higher buyout bid. That can produce a bidding war and the price of your shares can continue to rise until one of the suitors is the winner."
I agree....but I expect the share price to move up dramatically this month. And while you are correct about the AVERAGE premium what are the high end premiums? In some cases several hundred percent most years.
I was thinking about a potential buyout value for Sorrento stock.
I began with the analysts valuing the non-opioid pain program at $20+ per share.
Then I added my personal expectations that cancer programs are worth at least the same $20+ per share.
And then I concluded that the 11 Covid programs should be worth at least another $50+ per share.
I also expect BARDA grants and lawsuit proceeds will soon add another $1.5 Billion to the company value.
My conclusion is that a buyout would be in the $90+ range. As Henry is in no hurry to sell I expect partnerships first, followed by a buyout.
ACTUALLY 1499 is #5 on the list and both it and #22 are up on that site. Both yet to be announced.
https://www.clinicaltrials.gov/ct2/show/NCT04454398?term=sorrento&draw=1&rank=9
Shorters hate this list. They are now shortening it on Yahoo!. Omitting the last 10 items....wonder why? Sorrento has industry leading 11 Covid programs. Here is pending news update (as of July 1)
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
Sorrento has industry leading 11 Covid programs. Now with debt paid off here is pending news update (as of July 1)
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
How many Covid antibody and vaccine programs is Sorrento involved in? They list COVI-GUARD™, COVI-SHIELD™, COVIDTRAP™, ACE-MAB™, COVI-KILLER™ and COVI-CELL™, but we should include their 25% interest in Cellularitie's phase 1/2 CYNK-001. And then there are the two ARDS programs, phase 2 Abivirtinib and RTX. And then there is the very accurate, less than 8 minute test COVI-TRACK. And on July 1 we learned about the apparently 80% effective T-VIVA-19 vaccine, days after Fauci said he'd be satisfied with 70-75% effectiveness. So the total number of programs is now eleven (11). With the US doing very poorly in containing Covid (eg. Arizona, Texas and Florida) these test, antibodies and vaccines will be needed!
What a Sad day. Sad for Hindenberg. Sad for shorters Sad for shyster law firms. Sad. Sad. Sad.
Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2
July 01, 2020 12:06 ET | Source: Sorrento Therapeutics, Inc.
*T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.
*Novel protein to progress as priority vaccine candidate development program.
*Sorrento’s existing cGMP manufacturing facility bulk drug substance production capacity estimated able to satisfy up to 100 million doses a month, with on-site scale-up potential to meet additional demand as needed.
SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has published a pre-print publication (https://www.biorxiv.org/content/10.1101/2020.06.29.178616v1.full.pdf) describing initial pre-clinical results from its COVID-19 vaccination program, which introduced a novel targeted protein vaccine against COVID-19, referred to as T-VIVA-19.
T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc). The rS1-Fc was injected into either the vein or the thigh muscle of a mouse. The mice were given a booster shot three weeks later (by the same route as the initial injection) and immune responses to SARS-CoV-2 were examined.
Immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration. Antibodies were observed to be enhanced upon the administration of a booster. Approximately 80% of the mice’s sera possessed neutralizing antibodies and completely prevented virus infection in in vitro cell cultures using 100 TCID50 viruses and VERO cells.
Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, said, “If successful and approved, we plan to produce the T-VIVA-19 vaccine in our therapeutic antibody cGMP production facility in San Diego. Due to the potentially low dose administration of T-VIVA-19, which may be one milligram per person or less, we believe our existing cGMP manufacturing facility is capable of producing bulk drug substance rS1-Fc for up to 100 million doses a month. Unlike other vaccine candidates, our rS1-Fc protein production could utilize our existing therapeutic antibody manufacturing processes, and we therefore believe it would be simple and easy to scale up.”
Sorrento plans to take the T-VIVA-19 vaccine candidate through the regulatory steps for clinical trial clearance, while preparing for large scale manufacturing and commercial distribution in parallel.
Here's what Fauci says about vaccine effectiveness.
"When asked how effective the COVID-19 vaccine might be, since the flu vaccine is only around 40% to 60% protective most of the time, he said that remains uncertain. There is still plenty of testing to be done.
'The best we've ever done is measles, which is 97 to 98 percent effective,' said Fauci. 'That would be wonderful if we get there. I don't think we will. I would settle for [a] 70, 75% effective vaccine.'
Sorrento's vaccine's 80% effectiveness in animals, if continued in humans, would excede Fauci's guidance by a comfortable margin.
The vaccine results announced today are impressive....80% beats Fauci's 75% goal.
"... low-dose immunization with recombinant rS1-Fc administered intramuscularly mounted
considerable increased protection activity (80%) (Fig. 4H). Interestingly, routing rS1-Fc
administration via intravenous injection resulted in a similar protection efficacy (77.7%), indicating
that rS1-Fc immunization propagates a robust humoral immune response. "
Monoclonal Antibodies , Monoclonal Antibodies....are all over the news! Quess which company knew this months ago. Sorrento is a leader in this technology both in regard to Covid and cancer. I expect news this month regarding Sorrento Covid and cancer antibodies. Having a Billion antibody library helps explain why such a small biotech is becoming a leader in this technology just as it's needed most!
I expect a very busy July. Lots of news coming. But this is a wee week.
Thursday July 2 early close 2pm.
Friday July 3 closed for Revolution Day.
I think July will be the pivotal month for Sorrento. I expect...
1. Covid testing kit approval and several of the ten Covid treatment programs will enter the clinic plus Celularity interim results.
2. News on at least two blockbuster non-opioid pain trials should be released.
3. News on at least two cancer drug trials.
4. Partnerships potentially for Covid testing and treatments, non-opioid pain and cancer drugs.
5. Government Covid funding plus potential multi-billion out-of-court lawsuit settlement.
July and August are going to be very busy months for Sorrento.
How many Covid programs is Sorrento involved in? They list COVI-GUARD™, COVI-SHIELD™, COVIDTRAP™, ACE-MAB™, COVI-KILLER™ and COVI-CELL™, but we should include their 25% interest in Cellularitie's phase 1/2 CYNK-001. And then there are the two ARDS programs, phase 2 Abivirtinib and RTX. And finally the very accurate, less than 8 minute COVI-TRACK. This adds up to 10 (TEN) Covid programs, and there may be more coming! Surely Sorrento is the world's leader in Covid technologies. There's a lot of news coming!
I wouldn't be surprised to see some retail investors sell at $20. One analyst says the non-opioid portfolio is worth about much.
I believe the cancer and Covid portfolios are EACH worth more than that.
The last I saw Sorrento had about 209 million shares outstanding compared to Moderna's 371 million. I think any serious buy-out talks would begin at $80.
ANOTHER helpful post from Yahoo!
MikeD44
$SRNE @Deb Not one complaint has been filed in any federal or district court. No summons served upon Sorrento by any soliciting law firm alleging investor fraud based on a report from Hindenburg Research. Sorrento has not filed one 8K report disclosing legal service from any law firms threatening class action lawsuit based of Hindenburg's report. All of threats are advertisements directed at unfortunate shareholders who bought on the May 15th when company announced the discovery of STI-1499 to be a cure for COVID-19 ..same investors then panicked and sold at a lose on the following day after reading the press release by Hindenburg, who concocted a false narrative, calling the statement by Sorrento's leadership on the antibody's 100% inhibition of SARS-COV2.. a lie and an intentional pump & dump. Hindenburg & Viceroy known to be notorious short selling firms promulgated the entire storyline to create an opportunity to initiate a short position with Viceroy ..another short seller. Even the most uninformed casual observer would recognized the intent behind Hindenburg's claim. ABSOLUTELY NO False claims were made by Sorrento's leadership on their discovery. Henry Ji was clear.. the study conducted was "in vitro", (not in a living organism) in the lab & proved to provide 100% inhibition against the SARS-COV2 virus. In all reality it's entirely likely the advertising law firms are no where close to having sufficient support to move forward with litigation.
Nothing but shameless lies that in the end will amount to nothing but disservice to Sorrento's reputation throttling the shareprice lower. Thankfully investors have seen through the lie thrwarting these short selling firms from benefiting on their planned decitful trade.
For newbies here is pending news update (as of June 24) Note industry leading 8 Covid programs. This should have been in double digits weeks ago!
1. PSS lawsuit worth $1.2B+
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. Scilex potential IPO
18. FDA approval of COVI-TRACK
19. Sales begin for COVI-TRACK
20. Several cancer trials with first-in-class DAR-T are coming
21. Abivirtinib phase 2 in Covid begins in August
22. Water soluble CBD partnership
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
Another post from D44 that is interesting.
"Consider the current enterprise value. Think about the possibilty of a settlement as high as $1.3bl or low as $600ml based on damages sought on lost revenues from Cynvoliq. Think about the measurement that can be taken from the South Korean equivalent Genexol-PM by Samyang Biopharmaceuticals where depositions were ordered by the court . Genexol is already on the market having measurable revenues. Easy to assume Sorrento's settlement will be closer to the full damage claim.
Consider all of the possibilities for future revenue in the preclinical COVID INDs for treatments, prevention & testing. Then add the core oncology & pain candidates in clinical trials or preclinical study. Add ownership stakes 58% in Scilex, 35% in ImmuneOncia, 25% in Celularity, value in Yuhan, Bioserv & value of Sofusa Anti-PD1 & Anti- TNF. Tell me how you value the sum of parts. Current analytics from JMP & HCW show $5bln without COVID-19 candidates or settlement.
Will Henry sell before following through on the unknowns.. his SARS-COV2 INDs or prior to settling the PSS suit?
Possibly if the offer was over $8.5bl or $40 a share."
Excellent post on Yahoo!
MikeD44
Shorts are no longer able to keep Sorrento shares down. Their thesis weakened by the number & strength of Sorrento's near term catalysts. Investors are no longer fooled by baseless allegations of fraud by Hindenburg Research or Viceroy. Henry's claims of a cure insolating STI-1499 are valid. Upcoming COVID INDs & EUA are real.
No class action lawsuits summarily promoted by these known shortsellers have been filed by these bloodsniffing law firms. Their advertisements aren't gathering sufficient investor interest to file any suit. If one or two of them do file suit.. Sorrento as all other public companies have insurance to handle claims.
For years.. no news cycles used to allow shorts to concoct false narratives & as a result put buying became an opportunity. Those days are behind us. Look for fresh new highs between PRs with support that has holding power.